DEF: Ironwood Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting

Ironwood Pharmaceuticals will hold its 2025 annual meeting of stockholders virtually on June 10, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Ironwood Pharmaceuticals will hold its 2025 annual meeting of stockholders on June 10, 2025, at 9:00 a.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 15, 2025, are eligible to vote.
• The meeting will address the election of nine director nominees, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the company's auditors for 2025.
• The board of directors recommends voting for all director nominees, the advisory vote on executive compensation, and the ratification of the auditor selection.
• The proxy materials are available online, reducing delivery costs and environmental impact.
• The board of directors has nominated Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, and Jay Shepard for election as directors.
• The board determined that the 2024 company performance achievement multiplier was 70% for executive officers.
• The compensation and HR committee determined that each of the current named executive officers achieved or exceeded performance expectations for 2024.
• The company's insider trading prevention policy prohibits directors and executive officers from hedging or pledging company securities.
• The company has a clawback policy for recovering incentive-based compensation from executive officers in certain circumstances.
• The company's stock ownership guidelines require non-employee directors to hold shares worth at least three times their annual retainer.
• The company's stock ownership guidelines require the CEO to hold shares worth at least four times their annual base salary and executive officers to hold shares worth at least one times their annual base salary.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the upcoming annual meeting and related matters. While some financial targets were not met, the overall sentiment is stable, reflecting standard corporate governance procedures.

Positives

• The company is taking advantage of SEC rules to furnish proxy materials online, lowering costs and reducing environmental impact.
• The virtual stockholder format uses technology designed to provide stockholders rights and opportunities to participate in the virtual meeting similar to an in-person meeting.
• The company has a comprehensive code of business conduct and ethics.
• The company has corporate governance guidelines.
• The company has an insider trading prevention policy.
• The company has a clawback policy.
• The company has stock ownership guidelines for directors and executive officers.
• The company has an anti-overboarding policy limiting the number of other public company boards on which our directors may serve.

Negatives

• LINZESS U.S. net sales were $916.3 million for the year ended December 31, 2024, below the target of $1,087M.
• The company did not partner European Apraglutide rights.
• The company did not initiate Apraglutide new drug application (NDA) rolling submission and submit nonclinical and clinical NDA modules by target deadline.
• Adjusted EBITDA was $99.5 million for the year ended December 31, 2024, below the target of $162M.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• These risks and uncertainties could cause actual results to differ materially from those expressed or implied in such statements.
• Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, IW-3300, and our other product candidates; the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products commercial success; the risk that healthcare reform and other governmental and private payor initiatives may have an adverse effect upon or prevent our products or product candidates commercial success; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk that clinical programs and studies, including for linaclotide pediatric programs, apraglutide and IW-3300, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our ongoing and completed nonclinical studies and clinical trials may not be replicated in later trials or further data analyses and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the risk that we are unable to execute on our strategy to in-license externally developed products or product candidates; the risk that we are unable to successfully partner with other companies to develop and commercialize products or product candidates; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of any of our linaclotide pediatric programs, apraglutide and/or IW-3300 is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwoods or AbbVies accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could adversely affect our financial condition or restrict our future operations; and the risks listed under the heading Risk Factors and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our subsequent Securities and Exchange Commission filings.

Future Outlook

The proxy statement contains forward-looking statements about Ironwood's ability to execute its mission and strategy, but these statements are subject to risks and uncertainties.

Management Comments

• Thomas McCourt, Chief Executive Officer and Director: 'Sincerely, Thomas McCourt Chief Executive Officer and Director'

Industry Context

The document provides information on Ironwood Pharmaceuticals' corporate governance, executive compensation, and upcoming annual meeting, which are standard disclosures for publicly traded companies in the pharmaceutical industry.

Comparison to Industry Standards

• The peer group that Alpine proposed and that the compensation and HR committee used as a reference point in connection with 2024 compensation decisions is composed of the following 17 companies, which at the time they were designated as our peer group had a median 30-day average market capitalization of approximately $2.5 billion, median trailing twelve months revenue of approximately $407 million, a median of 513 employees, and a commercial drug on the market: ACADIA Pharmaceuticals, Inc. (Nasdaq: ACAD), Insmed, Inc. (Nasdaq: INSM), Alkermes plc (Nasdaq: ALKS), Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), Amicus Therapeutics, Inc. (Nasdaq: FOLD), Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), Ardelyx, Inc. (Nasdaq: ARDX), Pacira BioSciences, Inc. (Nasdaq: PCRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), PTC Therapeutics, Inc. (Nasdaq: PTCT), Blueprint Medicines Corporation (Nasdaq: BPMC), Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), Corcept Therapeutics Incorporated (Nasdaq: CORT), Travere Therapeutics, Inc. (Nasdaq: TVTX), Dynavax Technologies Corporation (Nasdaq: DVAX), Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), Halozyme Therapeutics, Inc. (Nasdaq: HALO).
• In September 2024, our compensation and HR committee approved a new peer group, which Alpine used as a reference point in advising our compensation and HR committee regarding compensation decisions made beginning in the fourth quarter of 2024.
• Alpine recommended that five companies (Alkermes plc, Blueprint Medicines Corporation, Halozyme Therapeutics, Inc., Insmed, Inc. and Ultragenyx Pharmaceutical Inc.) be removed from our existing peer group primarily due to high valuation compared to Ironwood and the other companies on the existing peer group and identified six companies (Arcutis Biotherapeutics, Inc., Collegium Pharmaceutical, Inc., Evlous, Inc., Innoviva, Inc., SAGE Therapeutics, Inc. and SIGA Technologies, Inc.), to replace those five companies.
• This updated peer group is comprised of the following 18 companies, which at the time of approval by our compensation and HR committee had a median 30-day average market capitalization of approximately $1.4 billion, median 1-year average market capitalization of approximately $1.3 billion, median trailing twelve months revenue of approximately $304 million, and a commercial drug on the market: ACADIA Pharmaceuticals, Inc. (Nasdaq: ACAD), Innoviva, Inc. (Nasdaq: INVA), Amicus Therapeutics, Inc. (Nasdaq: FOLD), Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), Ardelyx, Inc. (Nasdaq: ARDX), Pacira BioSciences, Inc. (Nasdaq: PCRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), PTC Therapeutics, Inc. (Nasdaq: PTCT), Collegium Pharmaceutical, Inc. (Nasdaq: COLL), SAGE Therapeutics, Inc. (Nasdaq: SAGE), Corcept Therapeutics Incorporated (Nasdaq: CORT), SIGA Technologies, Inc. (Nasdaq: SIGA), Dynavax Technologies Corporation (Nasdaq: DVAX), Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), Evlous, Inc. (Nasdaq: EOLS), Travere Therapeutics, Inc. (Nasdaq: TVTX).

Management Changes

Stakeholder Impact

• Stockholders are asked to vote on key company matters.
• Executive compensation is subject to stockholder advisory vote.
• The election of directors will shape the company's leadership and strategic direction.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the annual meeting on June 10, 2025.
• The company will announce the voting results after the annual meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, auditors, Ironwood Pharmaceuticals, stockholders, voting, LINZESS, apraglutide